DNB Asset Management AS boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,425 shares of the life sciences company’s stock after acquiring an additional 636 shares during the quarter. DNB Asset Management AS’s holdings in Illumina were worth $6,763,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of ILMN. Kaizen Advisory LLC boosted its stake in shares of Illumina by 161.0% in the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after purchasing an additional 227 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its stake in shares of Illumina by 2,670.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 9,345 shares during the last quarter. Sun Life Financial INC boosted its stake in shares of Illumina by 152.5% in the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after purchasing an additional 241 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Illumina by 3,192.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after purchasing an additional 415 shares during the last quarter. Finally, Hall Laurie J Trustee boosted its stake in shares of Illumina by 189.5% in the 2nd quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock valued at $154,000 after purchasing an additional 360 shares during the last quarter. 89.84% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $331.39, for a total value of $3,313,900.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 500 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $311.15, for a total transaction of $155,575.00. Following the completion of the transaction, the director now directly owns 6,139 shares of the company’s stock, valued at $1,910,149.85. The disclosure for this sale can be found here. Insiders sold 52,483 shares of company stock worth $17,702,063 over the last quarter. 0.54% of the stock is owned by corporate insiders.
NASDAQ ILMN opened at $321.69 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. Illumina, Inc. has a 12-month low of $198.21 and a 12-month high of $372.61. The company has a market capitalization of $53.96 billion, a PE ratio of 80.40, a price-to-earnings-growth ratio of 3.04 and a beta of 0.97.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.32. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The company had revenue of $830.00 million for the quarter, compared to the consensus estimate of $786.88 million. During the same period last year, the company earned $0.82 earnings per share. The firm’s revenue was up 25.4% compared to the same quarter last year. On average, analysts predict that Illumina, Inc. will post 5.46 EPS for the current fiscal year.
A number of brokerages recently weighed in on ILMN. Deutsche Bank increased their price target on shares of Illumina to $350.00 and gave the company a “buy” rating in a research report on Friday. ValuEngine downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday. UBS Group began coverage on shares of Illumina in a research report on Tuesday. They issued a “neutral” rating and a $340.00 price target on the stock. BidaskClub downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Finally, Piper Jaffray Companies increased their price target on shares of Illumina to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, October 2nd. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $324.76.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.